Linked Life Data

10545390

Source:http://linkedlifedata.com/resource/pubmed/id/10545390

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10545390rdf:typepubmed:Citationlld:pubmed
pubmed-article:10545390lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C0027765lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C0014063lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C0069428lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C1417228lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C1579762lld:lifeskim
pubmed-article:10545390lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:10545390pubmed:dateCreated1999-12-10lld:pubmed
pubmed-article:10545390pubmed:abstractTextIn experimental animal models of multiple sclerosis demyelinating antibody responses are directed against the myelin oligodendrocyte glycoprotein (MOG). We have investigated whether a similar antibody response is also present in multiple sclerosis patients. Using the recombinant human extracellular immunoglobulin domain of MOG (MOG-Ig) we have screened the sera and CSFs of 130 multiple sclerosis patients, 32 patients with other inflammatory neurological diseases (OIND), 30 patients with other non-inflammatory neurological diseases (ONND) and 10 patients with rheumatoid arthritis. We report that 38% of multiple sclerosis patients are seropositive for IgG antibodies to MOG-Ig compared with 28% seropositive for anti-myelin basic protein (MBP). In contrast, OIND are characterized by similar frequencies of serum IgG antibody responses to MOG-Ig (53%) and MBP (47%), whereas serum IgG responses to MOG-Ig are rare in ONND (3%) and rheumatoid arthritis (10%). Anti-MBP IgG antibodies, however, are a frequent finding in ONND (23%) and rheumatoid arthritis (60%). Our results provide clear evidence that anti-MOG-Ig antibodies are common in CNS inflammation. However, in OIND these antibody responses are transient, whereas they persist in multiple sclerosis. We demonstrate that the serum anti-MOG-Ig response is already established in early multiple sclerosis (multiple sclerosis-R0; 36%). In later multiple sclerosis stages frequencies and titres are comparable with early multiple sclerosis. In contrast, the frequency of anti-MBP antibodies is low in multiple sclerosis-R0 (12%) and increases during disease progression in relapsing-remitting (32%) and chronic progressive multiple sclerosis (40%), thus suggesting that anti-MBP responses accumulate over time. Finally we provide evidence for intrathecal synthesis of IgG antibodies to MOG-Ig in multiple sclerosis.lld:pubmed
pubmed-article:10545390pubmed:languageenglld:pubmed
pubmed-article:10545390pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10545390pubmed:statusMEDLINElld:pubmed
pubmed-article:10545390pubmed:monthNovlld:pubmed
pubmed-article:10545390pubmed:issn0006-8950lld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:BergerTTlld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:PoeweWWlld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:EgeTTlld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:LiningtonCClld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:DeisenhammerF...lld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:ReindlMMlld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:BrehmUUlld:pubmed
pubmed-article:10545390pubmed:authorpubmed-author:DilitzEElld:pubmed
pubmed-article:10545390pubmed:issnTypePrintlld:pubmed
pubmed-article:10545390pubmed:volume122 ( Pt 11)lld:pubmed
pubmed-article:10545390pubmed:ownerNLMlld:pubmed
pubmed-article:10545390pubmed:authorsCompleteYlld:pubmed
pubmed-article:10545390pubmed:pagination2047-56lld:pubmed
pubmed-article:10545390pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:meshHeadingpubmed-meshheading:10545390...lld:pubmed
pubmed-article:10545390pubmed:year1999lld:pubmed
pubmed-article:10545390pubmed:articleTitleAntibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.lld:pubmed
pubmed-article:10545390pubmed:affiliationDepartment of Neurology, University of Innsbruck, Innsbruck, Austria and Department of Neuroimmunology, Max Planck Institute for Neurobiology, Martinsried, Germany.lld:pubmed
pubmed-article:10545390pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10545390pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10545390pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10545390pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10545390lld:pubmed